(Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A))
Featured CDKN2A Categories
Recommended CDKN2A 抗体
Latest Publications on our CDKN2A Products: "Ezh2 programs TFH differentiation by integrating phosphorylation-dependent activation of Bcl6 and polycomb-dependent repression of p19Arf." in: Nature communications, Vol. 9, Issue 1, pp. 5452, (2019) (PubMed).
: "Canonical PRC2 function is essential for mammary gland development and affects chromatin compaction in mammary organoids." in: PLoS biology, Vol. 16, Issue 8, pp. e2004986, (2019) (PubMed).
: "p16Ink4a deletion in cells of the intervertebral disc affects their matrix homeostasis and senescence associated secretory phenotype without altering onset of senescence." in: Matrix biology : journal of the International Society for Matrix Biology, (2019) (PubMed).
: "CTGF Attenuates Tendon-Derived Stem/Progenitor Cell Aging." in: Stem cells international, Vol. 2019, pp. 6257537, (2019) (PubMed).
: "Resveratrol promotes oxidative stress to drive DLC1 mediated cellular senescence in cancer cells." in: Experimental cell research, Vol. 370, Issue 2, pp. 292-302, (2018) (PubMed).
: "Brain lipid-binding protein promotes proliferation and modulates cell cycle in C6 rat glioma cells." in: International journal of oncology, Vol. 51, Issue 5, pp. 1439-1448, (2018) (PubMed).
: "Cell-nonautonomous local and systemic responses to cell arrest enable long-bone catch-up growth in developing mice." in: PLoS biology, Vol. 16, Issue 6, pp. e2005086, (2018) (PubMed).
: "Loss of the clock gene PER2 is associated with cancer development and altered expression of important tumor-related genes in oral cancer." in: International journal of oncology, Vol. 52, Issue 1, pp. 279-287, (2018) (PubMed).
: "Spermidine prevents high glucose-induced senescence in HT-22 cells by upregulation of CB1 receptor." in: Clinical and experimental pharmacology & physiology, Vol. 45, Issue 8, pp. 832-840, (2018) (PubMed).
: "Development of core-shell nanocarrier system for augmenting piperine cytotoxic activity against human brain cancer cell line." in: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Vol. 118, pp. 103-112, (2018) (PubMed).
Synonyms and alternative names related to CDKN2Acyclin-dependent kinase inhibitor 2A (Cdkn2a), cyclin-dependent kinase inhibitor 2A (LOC100731972), cyclin-dependent kinase inhibitor 2A (LOC100340625), cyclin dependent kinase inhibitor 2A (CDKN2A), Arf, ARF, ARF-INK4a, CDK4I, CDKN2, CMM2, INK4, INK4A, INK4a-ARF, Ink4a/Arf, MLM, MTS-1, MTS1, P14, P14ARF, p16, P16, p16(INK4a), P16-INK4A, p16Cdkn2a, P16INK4, P16INK4A, p16INK4a, P19, p19
Protein level used designations for CDKN2A
- Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4)
- cell cycle inhibitor
- cell cycle regulator
- cyclin-dependent kinase 4 inhibitor A
- cyclin-dependent kinase inhibitor 2a p16Ink4a
- cyclin-dependent kinase inhibitor 2a p19Arf
- CDK4 inhibitor p16-INK4
- cell cycle negative regulator beta
- cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)
- multiple tumor suppressor 1
- cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4)
- cyclin-dependent kinase inhibitor 2A, isoforms 1/2
- cyclin-dependent kinase inhibitor protein
- mitochondrial smARF